-
C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag
Thursday, August 12, 2021 - 6:39am | 197Read More...The FDA has granted Orphan Drug Designation to C4 Therapeutics Inc (NASDAQ: CCCC) CFT7455 for multiple myeloma. CFT7455 is an orally bioavailable MonoDAC degrader targeting IKZF1/3. In June, C4 Therapeutics initiated a Phase 1/2 trial for CFT7455 to primarily investigate...
-
Sorrento Therapeutics To Start Testing DAR-T Cell Therapy In Multiple Myeloma Patients
Monday, August 2, 2021 - 12:40pm | 197Read More...The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR)-T Cell therapy for relapsed or refractory multiple myeloma. DAR-T technology is readily adaptable...
-
Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma
Monday, July 12, 2021 - 9:09am | 254Read More...The FDA has approved Janssen Biotech Inc's, a unit of Johnson & Johnson (NYSE: JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for multiple myeloma after first or subsequent relapse. Darzalex Faspro is co-formulated with recombinant human hyaluronidase PH20,...
-
Sanofi Bets Over $1B For Eureka's Multiple Myeloma Candidate
Tuesday, July 6, 2021 - 2:30pm | 231Read More...Sanofi SA (NASDAQ: SNY) has penned a licensing agreement with Eureka Therapeutics and Memorial Sloan Kettering Cancer Center for the non-CAR use of a new, human binding domain that targets G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D). Eureka...
-
Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial
Monday, June 28, 2021 - 9:16am | 174Read More...Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision's Phase 1/2a trial evaluating PBCAR269A. In the study, Precision's investigational allogeneic BCMA-...
-
Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models
Monday, June 14, 2021 - 12:59pm | 219Read More...Epizyme Inc (NASDAQ: EPZM) has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2. The chromosomal abnormality is responsible for about 15% to 20% of multiple myeloma cases and is associated with poor patient...
-
Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma
Monday, June 14, 2021 - 7:35am | 295Read More...Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced overall survival (OS) results from the Phase 3 MAIA study evaluating the Darzalex combo in patients with newly diagnosed multiple myeloma. After nearly five years of follow-up, median progression-...
-
Legend Biotech-Janssen's Multiple Myeloma Cell Therapy Under Review In US
Thursday, May 27, 2021 - 8:26am | 171Read More...Legend Biotech Corporation (NASDAQ: LEGN) has announced that the FDA accepted for priority review the marketing application submitted by Janssen Biotech Inc for ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. Cilta-cel is an investigational...
-
Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy
Thursday, May 13, 2021 - 6:52am | 223Read More...Celyad Oncology SA (NASDAQ: CYAD) has announced initial clinical data from the Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in patients with relapsed or refractory multiple myeloma. The data will be presented at the upcoming European Hematology Association (EHA)...
-
BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myeloma Patients
Tuesday, May 4, 2021 - 8:19am | 311Read More...BioLineRx (NASDAQ: BLRX) has announced positive top-line results from GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, combined with granulocyte colony-stimulating factor (G-CSF), for hematopoietic stem-cell mobilization for autologous bone marrow...
-
SpringWorks Therapeutics Stock Is Trading Higher After Nirogacestat Combo Study Starts Dosing In Multiple Myeloma Patients
Thursday, April 1, 2021 - 9:17am | 326Read More...SpringWorks Therapeutics Inc (NASDAQ: SWTX) has dosed the first patient in a Phase 1b clinical trial evaluating nirogacestat combined with Johnson & Johnson's (NYSE: JNJ)Janssen's teclistamab in patients with relapsed or refractory multiple myeloma....
-
Karyopharm's Partner Antengene Receives Priority Review For Selinexor Application In China
Wednesday, February 24, 2021 - 8:09am | 179Read More...Karyopharm Therapeutics Inc's (NASDAQ: KPTI) collaborating partner Antengene Corporation Limited has received priority review from China's National Medical Products Administration (NMPA) for ATG-010 (selinexor, XPOVIO). It is a first-in-class selective...
-
GlaxoSmithKline Gets FDA Approval For Blood Cancer Drug
Thursday, August 6, 2020 - 3:59am | 372Read More...GlaxoSmithKline plc (NYSE: GSK) announced Wednesday the United States Food and Drug Administration had approved its cancer drug aimed at treating refractory multiple myeloma in adults. What Happened The monotherapy, belantamab mafodotin, or BLENREP, stands approved for those patients who have...
-
Karyopharm Shares Nosedive On Tough FDA Briefing For Multiple Myeloma Drug
Friday, February 22, 2019 - 4:15pm | 513Read More...Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares were nosediving on roughly 11 times their average volume Friday following the release of the FDA briefing document prepared for review by the adcom panel that is evaluating the company's new drug application for selinexor. What Happened...
